Cathay Biotech Inc
Cathay Biotech Inc., together with its subsidiaries, engages in the research, development, production, and sale of bio-based materials in China and internationally. The company offers biological long-chain diacids, including sebacic acid and octadecanedioic acid; bio-based polyamides; and bio-based pentamethylene diamine under the TERRYL and ECOPENT brands. It also provides digital solutions for … Read more
Cathay Biotech Inc (688065) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.003x
Based on the latest financial reports, Cathay Biotech Inc (688065) has a cash flow conversion efficiency ratio of -0.003x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-66.22 Million) by net assets (CN¥21.22 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cathay Biotech Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Cathay Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cathay Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cathay Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
G Mining Ventures Corp
OTCQX:GMINF
|
0.076x |
|
Hiab B
HE:HIAB
|
0.018x |
|
China Everbright Environment Group Limited
F:CNE
|
-0.001x |
|
Photronics Inc
NASDAQ:PLAB
|
0.059x |
|
Zhejiang Weiming Environment Protection Co Ltd
SHG:603568
|
0.059x |
|
Beijing Orient Landscape Co Ltd
SHE:002310
|
0.009x |
|
Advanced Technology & Materials Co Ltd
SHE:000969
|
0.046x |
|
AVIC Capital Co Ltd
SHG:600705
|
-0.321x |
Annual Cash Flow Conversion Efficiency for Cathay Biotech Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Cathay Biotech Inc from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥15.10 Billion | CN¥820.93 Million | 0.054x | +41.03% |
| 2023-12-31 | CN¥14.77 Billion | CN¥569.45 Million | 0.039x | -27.87% |
| 2022-12-31 | CN¥15.04 Billion | CN¥803.67 Million | 0.053x | +32.10% |
| 2021-12-31 | CN¥14.69 Billion | CN¥594.18 Million | 0.040x | -9.78% |
| 2020-12-31 | CN¥11.48 Billion | CN¥514.96 Million | 0.045x | -42.12% |
| 2019-12-31 | CN¥4.64 Billion | CN¥359.62 Million | 0.077x | +2477.46% |
| 2018-12-31 | CN¥3.16 Billion | CN¥-10.29 Million | -0.003x | -113.39% |
| 2017-12-31 | CN¥2.20 Billion | CN¥53.45 Million | 0.024x | +123.05% |
| 2016-12-31 | CN¥1.22 Billion | CN¥-128.67 Million | -0.106x | -- |